<DOC>
	<DOC>NCT00892008</DOC>
	<brief_summary>This study is being conducted as a regulatory requirement post initial marketing authorization. This is primarily a safety study. This was an open label study and patients were enrolled once the decision to prescribe the medication was made by the Investigator.</brief_summary>
	<brief_title>A Post Marketing Surveillance Study On Pregabalin (Lyrica) On Efficacy, Safety And Tolerability Of Pregabalin</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Male or female, 18 years old and above diagnosed with neuropathic pain. Patients that are pregnant and lactating; and patients with known hypersensitivity to pregabalin or its related components.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>pregabalin</keyword>
	<keyword>neuropathic pain</keyword>
	<keyword>safety</keyword>
</DOC>